MX2019014842A - Uso de una combinación de ivosidenib y radiación para tratar gliomas. - Google Patents

Uso de una combinación de ivosidenib y radiación para tratar gliomas.

Info

Publication number
MX2019014842A
MX2019014842A MX2019014842A MX2019014842A MX2019014842A MX 2019014842 A MX2019014842 A MX 2019014842A MX 2019014842 A MX2019014842 A MX 2019014842A MX 2019014842 A MX2019014842 A MX 2019014842A MX 2019014842 A MX2019014842 A MX 2019014842A
Authority
MX
Mexico
Prior art keywords
methods
combination therapy
brain tumors
treating brain
treating
Prior art date
Application number
MX2019014842A
Other languages
English (en)
Inventor
David Schenkein
Nelamangala Nagaraja
Joshua Murtie
Brandon Nicolay
Katharine Yen
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2019014842A publication Critical patent/MX2019014842A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan métodos para tratar un tumor cerebral en un paciente que lo necesita que comprende administrar al paciente un compuesto descrito en la presente descripción y una terapia de radiación y/o uno o más agentes terapéuticos adicionales.
MX2019014842A 2017-06-12 2018-06-12 Uso de una combinación de ivosidenib y radiación para tratar gliomas. MX2019014842A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518562P 2017-06-12 2017-06-12
PCT/US2018/037066 WO2018231799A1 (en) 2017-06-12 2018-06-12 Methods of treating brain tumors using combination therapy

Publications (1)

Publication Number Publication Date
MX2019014842A true MX2019014842A (es) 2022-06-28

Family

ID=62779144

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014842A MX2019014842A (es) 2017-06-12 2018-06-12 Uso de una combinación de ivosidenib y radiación para tratar gliomas.

Country Status (12)

Country Link
US (2) US11458127B2 (es)
EP (1) EP3638236A1 (es)
JP (2) JP7263665B2 (es)
KR (1) KR20200027502A (es)
CN (1) CN111163776A (es)
AU (2) AU2018284104B2 (es)
BR (1) BR112019026435A2 (es)
CA (1) CA3067035A1 (es)
IL (1) IL271309A (es)
MX (1) MX2019014842A (es)
TW (1) TWI821189B (es)
WO (1) WO2018231799A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022021331A (ja) * 2020-07-21 2022-02-02 第一三共株式会社 テモゾロミドと変異型ｉｄｈ１酵素阻害剤の組み合わせ医薬

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478806A (en) 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
CA2184545A1 (en) 1996-07-31 1998-02-01 Pascale Reidenberg Cancer treatment with temozolomide
US9098521B2 (en) * 2010-09-15 2015-08-04 Qualcomm Incorporated System and method for managing resources and threshsold events of a multicore portable computing device
EP2721070A1 (en) 2011-06-17 2014-04-23 Harris, Adrian, L. Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies
US9474779B2 (en) * 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
JP6464085B2 (ja) 2012-08-07 2019-02-06 ジェネンテック， インコーポレイテッド 神経膠芽腫の治療のための併用療法
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3105210B1 (en) * 2014-02-11 2019-01-30 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
EA201890199A1 (ru) 2015-07-02 2018-06-29 Селджин Корпорейшн Комбинированная терапия для лечения гемобластозов и солидных опухолей
WO2017059224A2 (en) * 2015-10-01 2017-04-06 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
PL3362065T3 (pl) * 2015-10-15 2024-09-16 Les Laboratoires Servier Terapia skojarzona zawierająca iwosidenib, cytarabinę i daunorubicynę lub idarubicynę do leczenia ostrej białaczki szpikowej
HRP20211790T1 (hr) 2015-10-15 2022-03-04 Les Laboratoires Servier Kombinirana terapija za liječenje maligniteta

Also Published As

Publication number Publication date
EP3638236A1 (en) 2020-04-22
JP7263665B2 (ja) 2023-04-25
AU2018284104B2 (en) 2024-07-11
CN111163776A (zh) 2020-05-15
US20180353491A1 (en) 2018-12-13
TWI821189B (zh) 2023-11-11
US20200129491A1 (en) 2020-04-30
AU2024220102A1 (en) 2024-10-17
WO2018231799A1 (en) 2018-12-20
IL271309A (en) 2020-01-30
JP2020523344A (ja) 2020-08-06
WO2018231799A8 (en) 2020-01-09
AU2018284104A1 (en) 2020-01-16
JP2023022329A (ja) 2023-02-14
BR112019026435A2 (pt) 2020-07-14
US11458127B2 (en) 2022-10-04
CA3067035A1 (en) 2018-12-20
KR20200027502A (ko) 2020-03-12
TW201902480A (zh) 2019-01-16

Similar Documents

Publication Publication Date Title
IL281256A (en) Combined treatment for the treatment of triple-negative breast cancer
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
MX2018001659A (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
IL280707A (en) Diagnostic and therapeutic methods for treating breast cancer
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
WO2016025635A3 (en) Combination therapy for treating cancer
MX2021004828A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
SG10201902664RA (en) Combination therapy for treating cancer
WO2016043874A3 (en) Combination therapy for treating cancer
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020001727A (es) Terapia de combinacion.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2022003190A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
MX2019003751A (es) Proteina terapeutica.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2019014842A (es) Uso de una combinación de ivosidenib y radiación para tratar gliomas.
MX2019014934A (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.